title: COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Bertolino
authors.forename: Grazia
authors.initials: G
authors.lastname: Caforio
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Blasi
authors.forename: Antonio
authors.initials: A
authors.lastname: Rampino
authors.forename: Marcello
authors.initials: M
authors.lastname: Nardini
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Weinberger
authors.forename: Bruno
authors.initials: B
authors.lastname: Dallapiccola
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Sinibaldi
authors.forename: Sophia
authors.initials: S
authors.lastname: Douzgou
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D002394:Catechol O-Methyltransferase / Q000235:genetics*; D005838:Genotype; D006801:Humans; D008715:Methionine / Q000235:genetics; D000077152:Olanzapine; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data*; D012559:Schizophrenia / Q000175:diagnosis / Q000235:genetics*; D012565:Schizophrenic Psychology; D016896:Treatment Outcome; D014633:Valine / Q000235:genetics
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D008715:Methionine; D002394:Catechol O-Methyltransferase; D014633:Valine; D000077152:Olanzapine